Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS

NCT00082628 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT00082628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00082628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Lead sponsor
EMD Serono
Phase
Phase 3
Overall status
Completed
Start date
May 28, 2004
Completion date
September 28, 2005
Enrollment
326 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, lipodystrophy